tauvid Drug Patent Profile
✉ Email this page to a colleague
When do Tauvid patents expire, and when can generic versions of Tauvid launch?
Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-six patent family members in sixteen countries.
The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Tauvid
Tauvid was eligible for patent challenges on May 28, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 26, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for tauvid?
- What are the global sales for tauvid?
- What is Average Wholesale Price for tauvid?
Summary for tauvid
International Patents: | 26 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 9 |
Patent Applications: | 9 |
What excipients (inactive ingredients) are in tauvid? | tauvid excipients list |
DailyMed Link: | tauvid at DailyMed |
![tauvid drug patent expirations Drug patent expirations by year for tauvid](/p/graph/s/t/tauvid-patent-expirations.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for tauvid
Generic Entry Date for tauvid*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for tauvid
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Cleveland Clinic | Phase 1 |
Avid Radiopharmaceuticals | Phase 2 |
Avid Radiopharmaceuticals | Phase 1 |
US Patents and Regulatory Information for tauvid
tauvid is protected by one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of tauvid is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting tauvid
Imaging agents for detecting neurological dysfunction
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting tauvid
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-002 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-002 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-004 | Jul 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-003 | Jul 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for tauvid
When does loss-of-exclusivity occur for tauvid?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 12381042
Patent: Carboline and carbazole based imaging agents for detecting neurological dysfunction
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 15390
Patent: NOUVEAUX AGENTS D IMAGERIE POUR LA DETECTION D UNE DYSFONCTION NEUROLOGIQUE (NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up
Patent: 73963
Patent: AGENTS D'IMAGERIE A BASE DE CARBOLINE ET DE CARBAZOLE POUR LA DETECTION DE DYSFONCTION NEUROLOGIQUE (CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up
China
Patent: 4781234
Patent: Carboline and carbazole based imaging agents for detecting neurological dysfunction
Estimated Expiration: ⤷ Sign Up
Patent: 7011342
Patent: 用于检测神经功能障碍的基于咔啉和咔唑的成像剂 (CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 31359
Patent: Agentes de imagen para detectar disfunción neurológica
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0220401
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 47558
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 47558
Patent: NOUVEAUX AGENTS D'IMAGERIE POUR LA DÉTECTION D'UNE DYSFONCTION NEUROLOGIQUE (NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up
Patent: 99763
Patent: Nouveaux agents d'imagerie pour la détection d'un dysfonctionnement neurologique (Novel imaging agents for detecting neurological dysfunction)
Estimated Expiration: ⤷ Sign Up
Patent: 52572
Patent: AGENTS D'IMAGERIE À BASE DE CARBOLINE ET DE CARBAZOLE POUR LA DÉTECTION DE DYSFONCTION NEUROLOGIQUE (CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 58352
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 76206
Estimated Expiration: ⤷ Sign Up
Patent: 11512354
Estimated Expiration: ⤷ Sign Up
Patent: 15517572
Patent: 神経機能障害を検出するための造影剤
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 47558
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 47558
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 47558
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 47558
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1609504
Estimated Expiration: ⤷ Sign Up
Patent: 100135235
Patent: NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
Estimated Expiration: ⤷ Sign Up
Patent: 150002854
Patent: CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 92830
Estimated Expiration: ⤷ Sign Up
Patent: 07992
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering tauvid around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E058352 | ⤷ Sign Up | |
Portugal | 2247558 | ⤷ Sign Up | |
Japan | 2011512354 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2009102498 | ⤷ Sign Up | |
Lithuania | 2247558 | ⤷ Sign Up | |
China | 107011342 | 用于检测神经功能障碍的基于咔啉和咔唑的成像剂 (CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION) | ⤷ Sign Up |
Japan | 2015517572 | 神経機能障害を検出するための造影剤 | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |